A progressive decline in circulating CNP during natural aging is associated with increased LV fibrosis, and CNP exhibits direct antiproliferative actions on cardiac fibroblasts.
Answers are grounded in this paper and cite their sources.
CNP decline may drive age-related fibrosis in animal models; hypothesis-generating for human biomarker or therapeutic studies in HFpEF.
Myocardial aging is characterized by left ventricular (LV) fibrosis leading to diastolic and systolic dysfunction. Studies have established the potent antifibrotic and antiproliferative properties of C-type natriuretic peptide (CNP); however, the relationship between circulating CNP, LV fibrosis, and associated changes in LV function with natural aging are undefined. Accordingly, we characterized the relationship of plasma CNP with LV fibrosis and function in 2-, 11-, and 20-month-old male Fischer rats. Further in vitro, we established the antiproliferative actions of CNP and the participation of the clearance receptor using adult human cardiac fibroblasts. Here we establish for the first time that a progressive decline in circulating CNP characterizes natural aging and is strongly associated with a reciprocal increase in LV fibrosis that precedes impairment of diastolic and systolic function. Additionally, we demonstrate in cultured adult human cardiac fibroblasts that the direct antiproliferative actions of high-dose CNP may involve a non-cGMP pathway via the clearance receptor. Together, these studies provide new insights into myocardial aging and the relationship to the antifibrotic and antiproliferative peptide CNP.
No takes yet. Share an insight, caveat, or question.
Sangaralingham et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: